Molecular Templates, Inc. provided an update on its clinical-stage programs. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, ETBs are a potentially powerful therapeutic approach to selectively depleting immunosuppressive cells in oncology or eliminating self-reacting immune cells in severe immune-mediated diseases. The monotherapy activity with MT-6402 in relapsed/refractory solid tumor patients, and the clinical and ex vivo depletion of CD38+ immune cells seen with MT-0169 at well-tolerated doses underscore the potential of this platform across multiple diseases.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | -4.59% |
|
-21.21% | -72.12% |
03/06 | Molecular Templates, Inc. Provides Interim Update | CI |
15/05 | Earnings Flash (MTEM) MOLECULAR TEMPLATES Posts Q1 Revenue $11.1M | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-72.12% | 68.47L | |
+16.73% | 12TCr | |
+21.13% | 11TCr | |
+18.05% | 2.59TCr | |
-17.94% | 2.09TCr | |
-16.24% | 1.65TCr | |
-11.76% | 1.68TCr | |
-44.45% | 1.56TCr | |
+69.92% | 1.55TCr | |
+1.41% | 1.34TCr |
- Stock Market
- Equities
- MTEM Stock
- News Molecular Templates, Inc.
- Molecular Templates, Inc. Provides Interim Update